Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2022-05-04 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled 'INTERIM REPORT - Q1, 2022' and contains comprehensive financial statements (consolidated statement of comprehensive income, statement of financial position) for the period ending March 31, 2022. It includes management commentary, financial highlights, and operational updates, fitting the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-05-04 English
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage by a specific holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension). It explicitly mentions 'Reason for major shareholding notification Sell' and shows the 'Before the transaction' and 'After the transaction' holdings, including the resulting percentage (4.95493%). This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the code MRQ.
2022-04-22 English
Annual Report (ESEF) 2021
Annual Report (ESEF) Classification · 1% confidence FY 2021
2022-04-21 Swedish
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document details a change in shareholding percentage by a specific holder (Avanza Bank Holding AB for Avanza Pension) in Oncopeptides AB. It explicitly lists the 'Before the transaction' and 'After the transaction' quantities of shares and voting rights, culminating in a 'Total' percentage that crosses a threshold ('Flaggning sker för passerat tröskelvärde beträffande det aggregerade innehavet'). This structure—reporting changes in significant ownership levels crossing predefined thresholds—is characteristic of a Major Shareholding Notification. The filing type code corresponding to this is MRQ.
2022-04-06 Swedish
Antal aktier och röster i Oncopeptides
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release dated March 31, 2022, announcing a change in the total number of outstanding shares and votes due to the exercise of stock options under the company's incentive program. This directly relates to changes in the company's capital structure (share count and share capital). This aligns best with the 'Share Issue/Capital Change' definition (SHA). It is not a general earnings release (ER), a full annual report (10-K), or a dividend notice (DIV).
2022-03-31 Swedish
Number of shares and votes in Oncopeptides
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release dated March 31, 2022, announcing a change in the number of outstanding shares and votes due to the exercise of warrants under an incentive program. This directly relates to a change in the company's capital structure (share count and share capital increase). This aligns best with the 'Share Issue/Capital Change' definition (Code: SHA). It is not an earnings release (ER), a dividend notice (DIV), or a general regulatory filing (RNS), as it concerns a specific capital event.
2022-03-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.